RTTNews | Sep 17, 2021 07:34AM EDT

07:33 Friday, September 17, 2021 (RTTNews.com) - Roche (RHHBY) said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Gavreto (pralsetinib) as a monotherapy for the treatment of adult patients with rearranged during transfection fusion-positive advanced non-small cell lung cancer not previously treated with a RET inhibitor. The CHMP recommendation is based on the results of the phase I/II ARROW study. A final decision regarding the approval of Gavreto is anticipated in the coming months, the company said.

Blueprint Medicines and Roche are co-developing Gavreto globally, with the exception of certain territories in Asia, including China.

Read the original article on RTTNews ( https://www.rttnews.com/3226520/roche-announces-positive-chmp-opinion-for-gavreto-in-ret-fusion-positive-advanced-nsclc.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved